Leiio Innovations

Advancing and formulating and developing regulated novel psychoactive compounds.

Fundamentally, we believe there’s a broader application for psychedelic use beyond pharmaceutical drug development & clinical treatments.

The Leiio Innovation team, led by co-founders, Chris and Joe Claussen, and leading US mycologist, Christian Kaelin, develops novel IP and the foundation for a safe, standardized, and naturally-derived psilocybin supply chain for researchers, clinical applications, and eventually for our own premium branded sub-hallucinogenic dosed products. We believe psychedelic mushrooms unlock the potential of the brain to improve rather than degrade over time. We are working with leading research institutions to provide evidence of neurogenesis and neuroplasticity for applications in TBI, concussion, and overall wellness.